Cigna Group (CI) Stock News

The Schall Law Firm is seeking investors who purchased Lucid Group securities between February 25, 2026 and April 13, 2026 to join a class action lawsuit alleging securities fraud. The lawsuit claims Lucid made false and misleading statements about its manufacturing capabilities and overstated business strength while suffering material impacts from supplier quality issues that disrupted vehicle deliveries.

Faruqi & Faruqi, LLP is investigating securities fraud claims against Lucid Group, reminding investors of the July 28, 2026 deadline to seek lead plaintiff status. The lawsuit alleges that Lucid and its executives made false statements about manufacturing capabilities while concealing a supplier quality issue that disrupted Lucid Gravity deliveries. The disclosure of only 3,093 Q1 vehicles delivered, $280-284M revenue (vs. $433.8M consensus), and over $1B net loss caused significant stock price declines.

VANCOUVER, BC , June 12, 2026 /CNW/ - Wall Financial Corporation (the "Company") released its operating results and financial statements for the three months ended April 30, 2026. The Company recorded net earnings and comprehensive income attributable to shareholders of the Company for the three months ended April 30, 2026 of $4,250,854 or $0.13 per share compared to $5,680,721 or $0.18 per share in the same period of the prior year. Stabilized earnings from rental apartment operations decreased slightly from the previous year while earnings from the Company's hotels were stable year over year. Revenues and earnings from the Company's development operations decreased due to fewer condominium unit sales in the current period. Three months ended April 30 Statements of Earnings 2026 2025 Total revenue, investment and other income $ 37,309,620 Full story available on Benzinga.com

The Schall Law Firm is seeking investors who purchased Lucid Group securities between February 25, 2026 and April 13, 2026 to join a class action lawsuit alleging securities fraud. The lawsuit claims Lucid made false and misleading statements about its manufacturing capabilities and suffered material business impact from a supplier quality issue that disrupted vehicle deliveries.

Recludix Pharma announced preclinical data for REX-8756, an oral STAT6 inhibitor, demonstrating efficacy comparable to anti-IL-4/IL-13 antibody therapies in asthma and dermatitis models with a differentiated safety profile. The compound will be presented at EAACI and RAD congresses in June 2026. REX-8756 is currently in Phase 1 clinical trials under a partnership with Sanofi.

Novartis announced that Rhapsido (remibrutinib) met primary endpoints in the Phase III RemIND trial across three chronic inducible urticaria subtypes, demonstrating twice the symptom control rate versus placebo. The company has submitted an FDA application for the symptomatic dermographism subtype, with additional global regulatory filings planned for 2026. This represents the first targeted therapy for CIndU, addressing an unmet medical need affecting 29 million patients worldwide.

Law Offices of Howard G. Smith has announced securities fraud class action lawsuits against four publicly-traded companies. Calix faces allegations of misleading statements regarding margin pressures from memory component costs. AeroVironment is accused of overstating business prospects amid competitive threats. Zoetis is alleged to have concealed weakening demand for key products due to safety concerns and market competition. Lucid Group is charged with failing to disclose supplier quality issues affecting vehicle deliveries. All cases have lead plaintiff deadlines in late July 2026.

Sanofi discontinued its Phase 3 MOBILIZE study of riliprubart for CIDP patients due to failure to meet efficacy objectives. The setback highlights trial design challenges in CIDP studies and may strengthen Argenx's Vyvgart market position, which has demonstrated successful trial execution in the same indication.

Sanofi SA (NASDAQ: SNY ) on Wednesday announced that it will discontinue its Phase 3 MOBILIZE study evaluating riliprubart in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who had not responded to standard treatments. CIDP is a rare, acquired autoimmune disorder of the peripheral nervous system in which the body’s immune system attacks the myelin sheaths around nerve cells in the peripheral nervous system . The decision followed an assessment by an independent data monitoring committee, which determined that the study was not expected to meet its efficacy objectives. Sanofi said the review did not identify any safety concerns related to riliprubart. data-variant="card" data-news-mode="manual" > Read Also: FDA Approval Broadens Dupixent Use While Sanofi Posts Earnings Beat Sanofi To Review Broader Riliprubart Development Program The company said it will assess the future of other ongoing riliprubart studies, including the Phase 3 VITALIZE trial involving ... Full story available on Benzinga.com

A securities fraud class action lawsuit has been filed against Lucid Group, Inc. (LCID) alleging that the company failed to disclose a supplier quality issue that significantly disrupted Gravity deliveries between February 25, 2026 and April 13, 2026. The defendants allegedly overstated manufacturing capabilities and made materially misleading statements about the company's business and prospects. Investors with losses are invited to participate as lead plaintiffs before the July 28, 2026 deadline.

Rosen Law Firm has filed a class action lawsuit against Lucid Group, Inc. on behalf of investors who purchased securities between February 25, 2026 and April 13, 2026. The lawsuit alleges that Lucid made false and misleading statements regarding supplier quality issues that disrupted Lucid Gravity deliveries, overstated manufacturing capabilities, and failed to disclose material negative impacts on business and financial results. Investors who purchased during the class period may be entitled to compensation.

VINCI has signed an agreement with an investment service provider on June 10, 2026 to repurchase its own shares up to €200 million. The buyback program is valid from June 11 to July 31, 2026, with purchase prices not exceeding limits set by the general assembly.

VINCI signed a share purchase agreement on June 10th, 2026 with an investment services provider to repurchase its own shares up to €200 million between June 11th and July 31st, 2026. The buyback is authorized by the shareholders' meeting with a maximum purchase price limit.

Pomerantz LLP has filed a class action lawsuit against Lucid Group, Inc. on behalf of investors who purchased securities between February 25, 2026 and April 13, 2026. The lawsuit alleges that Lucid executives made false statements about manufacturing and delivery improvements while concealing significant supplier quality issues that disrupted Lucid Gravity deliveries for 29 days in Q1 2026. The company missed delivery estimates with only 3,093 vehicles delivered versus 5,500 produced, resulting in an 11.35% stock price decline and subsequent disclosure of massive operational losses exceeding $1 billion.

Avcon Industries, a subsidiary of Butler National Corporation, has received two FAA Supplemental Type Certificates (STCs) for the Bombardier Challenger 604, 605, and 650 aircraft platforms. The certifications approve installation of fuselage underside rail mounting provisions and radome systems for sensors and mission equipment, expanding Avcon's special mission aircraft modification portfolio and positioning the Challenger platforms as attractive options for customers requiring greater range, endurance, and payload capacity.

DBV Technologies announced positive Phase 3 VITESSE study results showing the VIASKIN® Peanut Patch demonstrated statistically significant efficacy versus placebo in children aged 4-7 years with peanut allergy who also have atopic comorbidities such as asthma, food allergies, or atopic dermatitis. The company also previewed its newly initiated Phase 2 THRIVE study, which will evaluate the patch's efficacy in infants aged 6-12 months with peanut allergy over three years of treatment.

DBV Technologies announced positive results from its Phase 3 VITESSE study showing that the VIASKIN® Peanut patch demonstrated statistically significant efficacy versus placebo in peanut-allergic children aged 4-7 years with concurrent atopic conditions including asthma, food allergies, and atopic dermatitis. The company also presented the design of its Phase 2 THRIVE study evaluating the patch in infants aged 6-12 months with peanut allergy, aiming to enable unrestricted peanut consumption after three years of treatment.

Lucid Group faces a securities class action lawsuit alleging material misstatements regarding supplier oversight and manufacturing capabilities. The company's 2025 Form 10-K claimed 'comprehensive' supplier qualification processes and 'strong relationships,' but an unauthorized supplier change and defective seatbelt welds on 4,476 Gravity SUVs halted deliveries for 29 days in February 2026, causing a $1.57 per share stock decline. Investors who purchased shares between February 25 and April 13, 2026 may be eligible for recovery.

MONTREAL , June 8, 2026 /CNW/ - Results For the three month period ended April 30, 2026, the Company's revenues decreased by ($8,548,000) to $141,576,000 compared to $150,124,000 recorded for the corresponding period of 2025, a decrease of (5.7%). This decrease is primarily attributable to the Tanguay division, whose revenue declined by ($8,853,000) or (5.9%). Same-store sales also decreased by (5.9%) during the period. Revenue from the real estate division increased by $305,000 compared with the corresponding period in 2025. Net loss for the three month period ended April 30, 2026, amounted to ($2,265,000) compared to the net loss of ($12,933,000) recorded for the corresponding period in 2025. Basic net earnings per share amounted to ($0.07) compared to ($0.40) recorded for the corresponding period in 2025. For the three month period ended April 30, 2026, there is no adjustment to net income. The change in net income amounted to $10,668,000, representing $0.33 per basic share. This variation, as well as that of the corresponding period, is explained as follows: (Unaudited and $ in thousands) April 30 2026 April 30 2025 Net earnings (2 265) (12 933) Minus: net earnings for the previous year (12 933) Variation 10 668 The variation in net adjusted earnings is allocated as follows: (Unaudited and $ in thousands) Increase (decrease) in retail operations Increase (decrease) in investments Increase (decrease) in investment properties Increase (decrease) in adjusted net earnings As at April 30, 2026 (8 128) 15 356 3 440 10 668 Retail division Net loss amounted to ($10,797,000), representing a decline of ($8,128,000) compared to the net loss for the corresponding period of 2025. This variance is primarily attributable to a (5.9%) decrease in sales recorded during the period, as well as higher fixed operating costs resulting from the rollout of outsourced warehousing and distr

ADARx Pharmaceuticals announced that Phase 1/2 clinical data for onvuzosiran (ADX-324), an siRNA therapeutic for hereditary angioedema (HAE), will be presented at the 2026 EAACI Annual Meeting in Istanbul. The drug is designed to reduce plasma kallikrein levels and prevent HAE attacks with reduced treatment burden. Onvuzosiran is currently in Phase 3 STOP-HAE trials and has received FDA Orphan Drug Designation.

Holzer & Holzer, LLC announced lead plaintiff deadlines for shareholder class action lawsuits against Calix, Inc., AeroVironment, Inc., and Lucid Group, Inc. The lawsuits allege materially false and misleading statements regarding advanced purchasing of memory components, competitive landscape misrepresentations, and manufacturing/delivery capability discrepancies. Investors who purchased shares during the specified periods and suffered losses are encouraged to seek legal representation.

Kymera Therapeutics announced preclinical data for KT-579, an oral IRF5 degrader, demonstrating disease-modifying activity in lupus models comparable or superior to approved therapies. The compound showed consistent activity across multiple disease pathways including Type I interferons and pro-inflammatory cytokines. Phase 1 healthy volunteer trial is ongoing with data expected in the second half of 2026, followed by a planned patient proof-of-concept trial in lupus.

Net Sales Increased 26.6% and Gross Profit Increased 42.4% in the Second Quarter of Fiscal 2026 Compared to Same Period in Prior Year ROANOKE, Va. , June 8, 2026 /PRNewswire/ -- Optical Cable Corporation (Nasdaq GM: OCC) ("OCC ® " or the "Company") today announced financial results for its second quarter of fiscal year 2026 ended April 30, 2026. Second Quarter 2026 Financial Results Consolidated net sales for the second quarter of fiscal year 2026 increased 26.6% to $22.2 million, compared to $17.5 million for the same period in the prior year. OCC experienced an increase in net sales in both its enterprise and specialty markets during the second quarter of fiscal year 2026, compared to the second quarter of fiscal year 2025. Sequentially, net sales for the second quarter of fiscal year 2026 increased 35.2% compared to $16.4 million for the first quarter of fiscal year 2026. OCC continues to see revenue growth and future growth opportunities in its targeted market sectors, both domestically and internationally – with robust demand from customers and end-users in the Company's enterprise, data center and severe duty market sectors. Net sales to customers in the United States increased 21.2% and net sales to customers outside of the United States increased 45.3% in the second quarter of fiscal year 2026, compared to the same period last year. At the end of the second quarter of fiscal year 2026, the Company's sales order backlog/forward load increased to $13.3 million when compared to $10.4 million as of January 31, 2026 (an increase of more than 27%), and when compared to $7.3 million as of October 31, 2025 (an increase of more than 82%). Gross profit increased 42.4% to $7.6 million in the second quarter of fiscal year 2026, compared to $5.3 million for the same period in fiscal year 2025, due to increased volumes and the resulting positive impact of OCC's manufac

VCI Global Limited (NASDAQ: VCIG) announced plans to launch Galactic OPC, a proprietary AI-native business operating system designed to help entrepreneurs and enterprises build, operate, and scale more efficiently in an AI-driven economy. The system will integrate intelligent software, high-performance GPU computing infrastructure, and collaborative innovation spaces through a digital platform and physical Galactic OPC Hub, featuring NVIDIA-powered GPU resources.

VCI Global Limited (NASDAQ: VCIG) announced the launch of Galactic OPC, an AI-native business operating system designed to help entrepreneurs and enterprises build, operate, and scale businesses in an AI-driven economy. The platform integrates intelligent software, GPU infrastructure, and collaborative innovation spaces through the Galactic OPC Hub, positioning AI as a core operational layer rather than just a productivity tool.

Rosen Law Firm has filed class action lawsuits against Lucid Group, Inc. and other companies on behalf of investors who purchased securities during specified periods. The Lucid lawsuit alleges that defendants made false statements regarding supplier quality issues that disrupted Gravity deliveries and overstated manufacturing capabilities, causing material financial impact. Investors who purchased during the Class Period (February 25, 2026 - April 13, 2026) may be entitled to compensation. The deadline to serve as lead plaintiff is July 28, 2026.

VanEck Bitcoin ETF (HODL) offers concentrated exposure to bitcoin with $1.1 billion in assets, while Hashdex Nasdaq Crypto Index US ETF (NCIQ) provides diversified exposure to both bitcoin and ether with $96.1 million in assets. Both funds charge 0.25% expense ratios and use spot assets rather than derivatives. The choice depends on whether investors prefer bitcoin's simplicity and institutional credibility or broader digital asset ecosystem exposure.

A securities fraud class action lawsuit has been filed against Lucid Group, Inc. for allegedly making false statements about its business operations. The lawsuit covers investors who purchased Lucid securities between February 25, 2026 and April 13, 2026. The company failed to disclose a supplier quality issue that significantly disrupted Lucid Gravity deliveries, resulting in missed revenue estimates and substantial losses. The deadline to file a lead plaintiff motion is July 28, 2026.

VCI Global announced plans to launch Galactic OPC, a proprietary AI-native business operating system designed to help entrepreneurs and businesses build and scale efficiently. The platform will integrate intelligent software, NVIDIA-powered GPU infrastructure, and the Galactic OPC Hub innovation center to create an ecosystem combining AI agents, computing resources, and business support services.

Rosen Law Firm has filed a class action lawsuit against Lucid Group, Inc. on behalf of investors who purchased securities between February 25, 2026 and April 13, 2026. The lawsuit alleges that Lucid made false and misleading statements regarding a supplier quality issue that disrupted Lucid Gravity deliveries and materially impacted the company's business and financial results. Investors who purchased during the class period may be entitled to compensation.